Apis Capital Advisors LLC Buys 210,000 Shares of Cellebrite DI Ltd. $CLBT

by · The Cerbat Gem

Apis Capital Advisors LLC lifted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 34.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 820,000 shares of the company’s stock after purchasing an additional 210,000 shares during the quarter. Cellebrite DI makes up about 2.6% of Apis Capital Advisors LLC’s portfolio, making the stock its 16th largest holding. Apis Capital Advisors LLC’s holdings in Cellebrite DI were worth $14,785,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Voss Capital LP boosted its position in shares of Cellebrite DI by 18.9% in the 4th quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock worth $145,142,000 after purchasing an additional 1,277,300 shares in the last quarter. Pertento Partners LLP boosted its position in shares of Cellebrite DI by 28.2% in the 4th quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock worth $107,447,000 after purchasing an additional 1,311,109 shares in the last quarter. Invesco Ltd. boosted its position in shares of Cellebrite DI by 58.6% in the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after purchasing an additional 2,054,644 shares in the last quarter. Granahan Investment Management LLC boosted its position in shares of Cellebrite DI by 16.3% in the 4th quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company’s stock worth $55,118,000 after purchasing an additional 427,719 shares in the last quarter. Finally, Cooper Creek Partners Management LLC bought a new stake in shares of Cellebrite DI in the 3rd quarter worth approximately $55,999,000. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Trading Down 2.7%

CLBT stock opened at $12.47 on Thursday. The stock has a market capitalization of $3.11 billion, a PE ratio of 44.54, a price-to-earnings-growth ratio of 1.59 and a beta of 1.17. Cellebrite DI Ltd. has a 12-month low of $11.02 and a 12-month high of $19.98. The stock’s 50 day simple moving average is $13.15 and its 200 day simple moving average is $14.95.

Analyst Upgrades and Downgrades

CLBT has been the topic of a number of analyst reports. Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. DA Davidson initiated coverage on Cellebrite DI in a research report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price target on the stock. Needham & Company LLC dropped their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Finally, Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.40.

Check Out Our Latest Research Report on Cellebrite DI

Insiders Place Their Bets

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the sale, the executive directly owned 440,101 shares in the company, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 13,269 shares of company stock worth $169,592. 5.70% of the stock is currently owned by insiders.

Cellebrite DI Company Profile

(Free Report)

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

Recommended Stories

Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report).